HUTCHMED (NASDAQ:HCM) Rating Lowered to Hold at Wall Street Zen

HUTCHMED (NASDAQ:HCM) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Several other research analysts also recently commented on HCM. Bank of America lifted their target price on shares of HUTCHMED from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, July 22nd. Zacks Research upgraded shares of HUTCHMED to a “strong-buy” rating in a report on Monday, August 11th. Finally, HSBC cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th.

HUTCHMED Price Performance

Shares of NASDAQ HCM opened at $16.45 on Friday. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.05. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $21.50. The firm’s fifty day moving average is $16.50 and its 200 day moving average is $15.18.

Institutional Investors Weigh In On HUTCHMED

Several large investors have recently bought and sold shares of HCM. M&G PLC grew its stake in shares of HUTCHMED by 0.4% during the 2nd quarter. M&G PLC now owns 259,617 shares of the company’s stock valued at $3,894,000 after purchasing an additional 924 shares during the period. Jane Street Group LLC grew its stake in shares of HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after purchasing an additional 124,771 shares during the period. Renaissance Technologies LLC grew its stake in shares of HUTCHMED by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company’s stock valued at $2,717,000 after purchasing an additional 29,239 shares during the period. XY Capital Ltd grew its stake in shares of HUTCHMED by 142.4% during the 1st quarter. XY Capital Ltd now owns 113,136 shares of the company’s stock valued at $1,702,000 after purchasing an additional 66,460 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares during the period. 8.82% of the stock is currently owned by institutional investors.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.